Association of HLA class I type with prevalence and outcome of
patients with acute myeloid leukemia and mutated nucleophosmin

J 2018

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin

KUZELOVA, Katerina; Barbora BRODSKA; Johannes SCHETELIG; Christoph ROLLING; Zdeněk RÁČIL et al.

Základní údaje

Originální název

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin

Autoři

Vydání

Plos one, San Francisco, Public Library of Science, 2018, 1932-6203

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.776

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/18:00106958

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Acute myeloid leukemia

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 2. 2019 20:46, Soňa Böhmová

Anotace

V originále

Acute myeloid leukemia with mutated nucleophosmin (NPMc+AML) forms a distinct AML subgroup with better prognosis which can potentially be associated with immune response against the mutated nucleophosmin (NPM). As the T-cell-mediated immunity involves antigen presentation on HLA class I molecules, we hypothesized that individuals with suitable HLA type could be less prone to develop NPMc+AML. We compared HLA class I distribution in NPMc+AML patient cohort (398 patients from 5 centers) with the HLA allele frequencies of the healthy population and found HLA-A*02, B*07, B*40 and C*07 underrepresented in the NPMc+AML group. Presence of B*07 or C*07:01 antigen was associated with better survival in patients without concomitant FLT3 internal tandem duplication. Candidate NPM-derived immunopeptides were found for B*40 and B*07 using prediction software tools. Our findings suggest that a T-cell-mediated immune response could actually explain better prognosis of NPMc+ patients and provide a rationale for attempts to explore the importance of immunosuppressive mechanisms in this AML subgroup.

Návaznosti

NV15-25809A, projekt VaV

Název: Národní program studia mutací a klonality leukemických buněk u pacientů s akutní myeloidní leukémií

Citovat

KUZELOVA, Katerina; Barbora BRODSKA; Johannes SCHETELIG; Christoph ROLLING; Zdeněk RÁČIL; Juliane Stickel WALZ; Grzegorz HELBIG; Ota FUCHS; Milena VRANA; Pavla PECHERKOVA; Cyril SALEK a Jiří MAYER. Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin. Plos one. San Francisco: Public Library of Science, 2018, roč. 13, č. 12, s. 1-12. ISSN 1932-6203. Dostupné z: https://doi.org/10.1371/journal.pone.0204290.

@article{1482571,
   author = {Kuzelova, Katerina and Brodska, Barbora and Schetelig, Johannes and Rolling, Christoph and Ráčil, Zdeněk and Walz, Juliane Stickel and Helbig, Grzegorz and Fuchs, Ota and Vrana, Milena and Pecherkova, Pavla and Salek, Cyril and Mayer, Jiří},
   article_location = {San Francisco},
   article_number = {12},
   doi = {https://doi.org/10.1371/journal.pone.0204290},
   keywords = {Acute myeloid leukemia},
   language = {eng},
   issn = {1932-6203},
   journal = {Plos one},
   title = {Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin},
   volume = {13},
   year = {2018}
}

TY  - JOUR
ID  - 1482571
AU  - Kuzelova, Katerina - Brodska, Barbora - Schetelig, Johannes - Rolling, Christoph - Ráčil, Zdeněk - Walz, Juliane Stickel - Helbig, Grzegorz - Fuchs, Ota - Vrana, Milena - Pecherkova, Pavla - Salek, Cyril - Mayer, Jiří
PY  - 2018
TI  - Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin
JF  - Plos one
VL  - 13
IS  - 12
SP  - 1-12
EP  - 1-12
PB  - Public Library of Science
SN  - 19326203
KW  - Acute myeloid leukemia
N2  - Acute myeloid leukemia with mutated nucleophosmin (NPMc+AML) forms a distinct AML subgroup with better prognosis which can potentially be associated with immune response against the mutated nucleophosmin (NPM). As the T-cell-mediated immunity involves antigen presentation on HLA class I molecules, we hypothesized that individuals with suitable HLA type could be less prone to develop NPMc+AML. We compared HLA class I distribution in NPMc+AML patient cohort (398 patients from 5 centers) with the HLA allele frequencies of the healthy population and found HLA-A*02, B*07, B*40 and C*07 underrepresented in the NPMc+AML group. Presence of B*07 or C*07:01 antigen was associated with better survival in patients without concomitant FLT3 internal tandem duplication. Candidate NPM-derived immunopeptides were found for B*40 and B*07 using prediction software tools. Our findings suggest that a T-cell-mediated immune response could actually explain better prognosis of NPMc+ patients and provide a rationale for attempts to explore the importance of immunosuppressive mechanisms in this AML subgroup.
ER  -

KUZELOVA, Katerina; Barbora BRODSKA; Johannes SCHETELIG; Christoph ROLLING; Zdeněk RÁČIL; Juliane Stickel WALZ; Grzegorz HELBIG; Ota FUCHS; Milena VRANA; Pavla PECHERKOVA; Cyril SALEK a Jiří MAYER. Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin. \textit{Plos one}. San Francisco: Public Library of Science, 2018, roč.~13, č.~12, s.~1-12. ISSN~1932-6203. Dostupné z: https://doi.org/10.1371/journal.pone.0204290.

Přehled o publikaci